Anastrozole
Phase
Phase2Study status
CompletedView details
ARVINAS, INC.
IndicationBreast Cancer
Actual study completion2024-07-25
Dr. Izzy’s FDA Radar
16 biotech companies scanned · Verified studies linked to 8
| Timing | ||||||
|---|---|---|---|---|---|---|
| ARVN ARVINAS, INC. | Anastrozole | Breast Cancer | Phase2 | Completed | Actual study completion2024-07-25 | NCT05549505 |
| ARVN ARVINAS, INC. | ARV-110 | Prostate Cancer Metastatic | Phase1 / Phase2 | Completed | Actual study completion2025-01-27 | NCT03888612 |
| ARVN ARVINAS, INC. | ARV-393 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase1 | Recruiting | NCT06393738 | |
| ARVN ARVINAS, INC. | ARV-471 | Breast Cancer | Phase2 | Completed | Actual study completion2024-07-25 | NCT05549505 |
| ARVN ARVINAS, INC. | ARV-6723 | Advanced Solid Tumor | Phase1 / Phase2 | Recruiting | Estimated study completion2032-03-31 Announced catalyst timingH2 2027 | NCT07749586 |
| ARVN ARVINAS, INC. | ARV-806 | KRAS G12D Mutation; Advanced Solid Cancer | Phase1 / Phase2 | Active not recruiting | Estimated study completion2026-11-30 | NCT07023731 |
| ARVN ARVINAS, INC. | Glofitamab | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | Phase1 | Recruiting | NCT06393738 | |
| ARVN ARVINAS, INC. | Pembrolizumab | Advanced Solid Tumor | Phase1 / Phase2 | Recruiting | Estimated study completion2032-03-31 Announced catalyst timingH2 2027 | NCT07749586 |
| ARVN ARVINAS, INC. | SOC | Advanced Solid Tumor | Phase1 / Phase2 | Recruiting | Estimated study completion2032-03-31 Announced catalyst timingH2 2027 | NCT07749586 |
| AXSM Axsome Therapeutics, Inc. | AXS-02 | Osteoarthritis, Knee | Phase3 | Unknown | Estimated study completion2020-12 | NCT02746068 |
| AXSM Axsome Therapeutics, Inc. | AXS-02 (oral zoledronate) | Complex Regional Pain Syndrome; Reflex Sympathetic Dystrophy | Phase3 | Unknown | Estimated study completion2019-01 | NCT02504008 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Treatment Resistant Major Depressive Disorder | Phase3 | Completed | Actual study completion2020-03-20 | NCT02741791 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor | Phase2 / Phase3 | Completed | Actual study completion2020-04-17 | NCT03226522 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Major Depressive Disorder | Phase2 | Completed | Actual study completion2019-01-07 | NCT03595579 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Depression; Major Depressive Disorder | Phase3 | Completed | Actual study completion2019-12-05 | NCT04019704 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Treatment Resistant Depression; Major Depressive Disorder | Phase2 | Completed | Actual study completion2021-07-30 | NCT04608396 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor | Phase3 | Completed | Actual study completion2022-11-21 | NCT04797715 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Major Depressive Disorder; Treatment Resistant Depression | Phase2 | Unknown | Estimated study completion2021-07 | NCT04971291 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation | Phase3 | Completed | Actual study completion2024-12-21 | NCT05557409 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 | Major Depressive Disorder | Phase4 | Recruiting | Estimated study completion2026-03 | NCT06223880 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 (dextromethorphan and bupropion) oral tablets | Major Depressive Disorder; Treatment Resistant Depression; Depression | Phase3 | Completed | Actual study completion2020-10-23 | NCT04039022 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 (dextromethorphan-bupropion) | Treatment Resistant Depression; Major Depressive Disorder | Phase2 | Terminated | Actual study completion2022-03-04 | NCT04634669 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 (dextromethorphan-bupropion) | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomotor | Phase3 | Completed | Actual study completion2024-12-21 | NCT04947553 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 (dextromethorphan-bupropion) | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomotor | Phase3 | Terminated | Actual study completion2025-04-25 | NCT06736509 |
| AXSM Axsome Therapeutics, Inc. | AXS-05 (dextromethorphan-bupropion) | Smoking Cessation | Phase3 | Recruiting | Estimated study completion2027-12 | NCT07766655 |
Phase
Phase2Study status
CompletedARVINAS, INC.
IndicationBreast Cancer
Actual study completion2024-07-25
Phase
Phase1 / Phase2Study status
CompletedARVINAS, INC.
IndicationProstate Cancer Metastatic
Actual study completion2025-01-27
Phase
Phase1Study status
RecruitingPhase
Phase2Study status
CompletedARVINAS, INC.
IndicationBreast Cancer
Actual study completion2024-07-25
Phase
Phase1 / Phase2Study status
RecruitingARVINAS, INC.
IndicationAdvanced Solid Tumor
Estimated study completion2032-03-31
Announced catalyst timingH2 2027
Phase
Phase1 / Phase2Study status
Active not recruitingARVINAS, INC.
IndicationKRAS G12D Mutation; Advanced Solid Cancer
Estimated study completion2026-11-30
Phase
Phase1Study status
RecruitingPhase
Phase1 / Phase2Study status
RecruitingARVINAS, INC.
IndicationAdvanced Solid Tumor
Estimated study completion2032-03-31
Announced catalyst timingH2 2027
Phase
Phase1 / Phase2Study status
RecruitingARVINAS, INC.
IndicationAdvanced Solid Tumor
Estimated study completion2032-03-31
Announced catalyst timingH2 2027
Phase
Phase3Study status
UnknownAxsome Therapeutics, Inc.
IndicationOsteoarthritis, Knee
Estimated study completion2020-12
Phase
Phase3Study status
UnknownAxsome Therapeutics, Inc.
IndicationComplex Regional Pain Syndrome; Reflex Sympathetic Dystrophy
Estimated study completion2019-01
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationTreatment Resistant Major Depressive Disorder
Actual study completion2020-03-20
Phase
Phase2 / Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor
Actual study completion2020-04-17
Phase
Phase2Study status
CompletedAxsome Therapeutics, Inc.
IndicationMajor Depressive Disorder
Actual study completion2019-01-07
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationDepression; Major Depressive Disorder
Actual study completion2019-12-05
Phase
Phase2Study status
CompletedAxsome Therapeutics, Inc.
IndicationTreatment Resistant Depression; Major Depressive Disorder
Actual study completion2021-07-30
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor
Actual study completion2022-11-21
Phase
Phase2Study status
UnknownAxsome Therapeutics, Inc.
IndicationMajor Depressive Disorder; Treatment Resistant Depression
Estimated study completion2021-07
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation
Actual study completion2024-12-21
Phase
Phase4Study status
RecruitingAxsome Therapeutics, Inc.
IndicationMajor Depressive Disorder
Estimated study completion2026-03
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationMajor Depressive Disorder; Treatment Resistant Depression; Depression
Actual study completion2020-10-23
Phase
Phase2Study status
TerminatedAxsome Therapeutics, Inc.
IndicationTreatment Resistant Depression; Major Depressive Disorder
Actual study completion2022-03-04
Phase
Phase3Study status
CompletedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomotor
Actual study completion2024-12-21
Phase
Phase3Study status
TerminatedAxsome Therapeutics, Inc.
IndicationAgitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation, Psychomotor
Actual study completion2025-04-25
Phase
Phase3Study status
RecruitingAxsome Therapeutics, Inc.
IndicationSmoking Cessation
Estimated study completion2027-12
Page 1 of 14
16 of 16 biotech companies scanned. Verified studies are linked to 8 companies; sponsor associations for the remaining companies are not yet verified.
3189 unresolved sponsor matches · 0 source failures
Exact SEC legal-entity lead sponsors only. Subsidiaries, collaborators and unresolved sponsor aliases remain unlinked. Registry study completion is not an announced catalyst or readout date. Drug names and study phases retain registry wording; differently named interventions are not merged.
Independent tracker · Official ClinicalTrials.gov records · Daily refresh